Split (3)

train · 43.5k rows

serial-number stringlengths 7 11	id stringlengths 7 11	event stringclasses 2 values	trigger listlengths 1 1	is-multi-event bool 2 classes	context stringlengths 24 527	argument-type stringclasses 3 values	role stringclasses 15 values	raw-initial-ground-truth listlengths 1 6
train-201	14557583_2	adverse_event	[ "induced" ]	false	L-DOPA-induced excessive daytime sleepiness in PD: a placebo-controlled case with MSLT assessment.	subject	subject-gender	[ "null" ]
train-202	14557583_2	adverse_event	[ "induced" ]	false	L-DOPA-induced excessive daytime sleepiness in PD: a placebo-controlled case with MSLT assessment.	subject	subject-population	[ "null" ]
train-203	14557583_2	adverse_event	[ "induced" ]	false	L-DOPA-induced excessive daytime sleepiness in PD: a placebo-controlled case with MSLT assessment.	subject	subject-race	[ "null" ]
train-204	14557583_2	adverse_event	[ "induced" ]	false	L-DOPA-induced excessive daytime sleepiness in PD: a placebo-controlled case with MSLT assessment.	treatment	treatment-drug	[ "DOPA" ]
train-205	14557583_2	adverse_event	[ "induced" ]	false	L-DOPA-induced excessive daytime sleepiness in PD: a placebo-controlled case with MSLT assessment.	treatment	treatment-disorder	[ "null" ]
train-206	14557583_2	adverse_event	[ "induced" ]	false	L-DOPA-induced excessive daytime sleepiness in PD: a placebo-controlled case with MSLT assessment.	treatment	treatment-route	[ "null" ]
train-207	14557583_2	adverse_event	[ "induced" ]	false	L-DOPA-induced excessive daytime sleepiness in PD: a placebo-controlled case with MSLT assessment.	treatment	treatment-dosage	[ "null" ]
train-208	14557583_2	adverse_event	[ "induced" ]	false	L-DOPA-induced excessive daytime sleepiness in PD: a placebo-controlled case with MSLT assessment.	treatment	treatment-time_elasped	[ "null" ]
train-209	14557583_2	adverse_event	[ "induced" ]	false	L-DOPA-induced excessive daytime sleepiness in PD: a placebo-controlled case with MSLT assessment.	treatment	treatment-duration	[ "null" ]
train-210	14557583_2	adverse_event	[ "induced" ]	false	L-DOPA-induced excessive daytime sleepiness in PD: a placebo-controlled case with MSLT assessment.	treatment	treatment-freq	[ "null" ]
train-211	8384030_1	adverse_event	[ "contributed" ]	false	CONCLUSIONS: It is probable that foscarnet contributed to the electrolyte disorders and symptomatology in this patient.	main-arguments	subject	[ "this patient" ]
train-212	8384030_1	adverse_event	[ "contributed" ]	false	CONCLUSIONS: It is probable that foscarnet contributed to the electrolyte disorders and symptomatology in this patient.	main-arguments	treatment	[ "foscarnet" ]
train-213	8384030_1	adverse_event	[ "contributed" ]	false	CONCLUSIONS: It is probable that foscarnet contributed to the electrolyte disorders and symptomatology in this patient.	main-arguments	effect	[ "electrolyte disorders and symptomatology" ]
train-214	8384030_1	adverse_event	[ "contributed" ]	false	CONCLUSIONS: It is probable that foscarnet contributed to the electrolyte disorders and symptomatology in this patient.	subject	subject-age	[ "null" ]
train-215	8384030_1	adverse_event	[ "contributed" ]	false	CONCLUSIONS: It is probable that foscarnet contributed to the electrolyte disorders and symptomatology in this patient.	subject	subject-disorder	[ "null" ]
train-216	8384030_1	adverse_event	[ "contributed" ]	false	CONCLUSIONS: It is probable that foscarnet contributed to the electrolyte disorders and symptomatology in this patient.	subject	subject-gender	[ "null" ]
train-217	8384030_1	adverse_event	[ "contributed" ]	false	CONCLUSIONS: It is probable that foscarnet contributed to the electrolyte disorders and symptomatology in this patient.	subject	subject-population	[ "null" ]
train-218	8384030_1	adverse_event	[ "contributed" ]	false	CONCLUSIONS: It is probable that foscarnet contributed to the electrolyte disorders and symptomatology in this patient.	subject	subject-race	[ "null" ]
train-219	8384030_1	adverse_event	[ "contributed" ]	false	CONCLUSIONS: It is probable that foscarnet contributed to the electrolyte disorders and symptomatology in this patient.	treatment	treatment-drug	[ "foscarnet" ]
train-220	8384030_1	adverse_event	[ "contributed" ]	false	CONCLUSIONS: It is probable that foscarnet contributed to the electrolyte disorders and symptomatology in this patient.	treatment	treatment-disorder	[ "null" ]
train-221	8384030_1	adverse_event	[ "contributed" ]	false	CONCLUSIONS: It is probable that foscarnet contributed to the electrolyte disorders and symptomatology in this patient.	treatment	treatment-route	[ "null" ]
train-222	8384030_1	adverse_event	[ "contributed" ]	false	CONCLUSIONS: It is probable that foscarnet contributed to the electrolyte disorders and symptomatology in this patient.	treatment	treatment-dosage	[ "null" ]
train-223	8384030_1	adverse_event	[ "contributed" ]	false	CONCLUSIONS: It is probable that foscarnet contributed to the electrolyte disorders and symptomatology in this patient.	treatment	treatment-time_elasped	[ "null" ]
train-224	8384030_1	adverse_event	[ "contributed" ]	false	CONCLUSIONS: It is probable that foscarnet contributed to the electrolyte disorders and symptomatology in this patient.	treatment	treatment-duration	[ "null" ]
train-225	8384030_1	adverse_event	[ "contributed" ]	false	CONCLUSIONS: It is probable that foscarnet contributed to the electrolyte disorders and symptomatology in this patient.	treatment	treatment-freq	[ "null" ]
train-226	17228132_1	adverse_event	[ "due" ]	false	Acute drug induced hepatitis due to erlotinib.	main-arguments	subject	[ "null" ]
train-227	17228132_1	adverse_event	[ "due" ]	false	Acute drug induced hepatitis due to erlotinib.	main-arguments	treatment	[ "erlotinib" ]
train-228	17228132_1	adverse_event	[ "due" ]	false	Acute drug induced hepatitis due to erlotinib.	main-arguments	effect	[ "Acute drug induced hepatitis" ]
train-229	17228132_1	adverse_event	[ "due" ]	false	Acute drug induced hepatitis due to erlotinib.	subject	subject-age	[ "null" ]
train-230	17228132_1	adverse_event	[ "due" ]	false	Acute drug induced hepatitis due to erlotinib.	subject	subject-disorder	[ "null" ]
train-231	17228132_1	adverse_event	[ "due" ]	false	Acute drug induced hepatitis due to erlotinib.	subject	subject-gender	[ "null" ]
train-232	17228132_1	adverse_event	[ "due" ]	false	Acute drug induced hepatitis due to erlotinib.	subject	subject-population	[ "null" ]
train-233	17228132_1	adverse_event	[ "due" ]	false	Acute drug induced hepatitis due to erlotinib.	subject	subject-race	[ "null" ]
train-234	17228132_1	adverse_event	[ "due" ]	false	Acute drug induced hepatitis due to erlotinib.	treatment	treatment-drug	[ "erlotinib" ]
train-235	17228132_1	adverse_event	[ "due" ]	false	Acute drug induced hepatitis due to erlotinib.	treatment	treatment-disorder	[ "null" ]
train-236	17228132_1	adverse_event	[ "due" ]	false	Acute drug induced hepatitis due to erlotinib.	treatment	treatment-route	[ "null" ]
train-237	17228132_1	adverse_event	[ "due" ]	false	Acute drug induced hepatitis due to erlotinib.	treatment	treatment-dosage	[ "null" ]
train-238	17228132_1	adverse_event	[ "due" ]	false	Acute drug induced hepatitis due to erlotinib.	treatment	treatment-time_elasped	[ "null" ]
train-239	17228132_1	adverse_event	[ "due" ]	false	Acute drug induced hepatitis due to erlotinib.	treatment	treatment-duration	[ "null" ]
train-240	17228132_1	adverse_event	[ "due" ]	false	Acute drug induced hepatitis due to erlotinib.	treatment	treatment-freq	[ "null" ]
train-241	9804082_2	adverse_event	[ "after" ]	false	We observed 3 diabetic patients with intolerable dizziness followed by nausea and vomiting immediately after an initial administration of the alpha-glucosidase inhibitor, voglibose.	main-arguments	subject	[ "3 diabetic patients" ]
train-242	9804082_2	adverse_event	[ "after" ]	false	We observed 3 diabetic patients with intolerable dizziness followed by nausea and vomiting immediately after an initial administration of the alpha-glucosidase inhibitor, voglibose.	main-arguments	treatment	[ "an initial administration of the alpha-glucosidase inhibitor, voglibose" ]
train-243	9804082_2	adverse_event	[ "after" ]	false	We observed 3 diabetic patients with intolerable dizziness followed by nausea and vomiting immediately after an initial administration of the alpha-glucosidase inhibitor, voglibose.	main-arguments	effect	[ "intolerable dizziness followed by nausea and vomiting" ]
train-244	9804082_2	adverse_event	[ "after" ]	false	We observed 3 diabetic patients with intolerable dizziness followed by nausea and vomiting immediately after an initial administration of the alpha-glucosidase inhibitor, voglibose.	subject	subject-age	[ "null" ]
train-245	9804082_2	adverse_event	[ "after" ]	false	We observed 3 diabetic patients with intolerable dizziness followed by nausea and vomiting immediately after an initial administration of the alpha-glucosidase inhibitor, voglibose.	subject	subject-disorder	[ "diabetic" ]
train-246	9804082_2	adverse_event	[ "after" ]	false	We observed 3 diabetic patients with intolerable dizziness followed by nausea and vomiting immediately after an initial administration of the alpha-glucosidase inhibitor, voglibose.	subject	subject-gender	[ "null" ]
train-247	9804082_2	adverse_event	[ "after" ]	false	We observed 3 diabetic patients with intolerable dizziness followed by nausea and vomiting immediately after an initial administration of the alpha-glucosidase inhibitor, voglibose.	subject	subject-population	[ "3" ]
train-248	9804082_2	adverse_event	[ "after" ]	false	We observed 3 diabetic patients with intolerable dizziness followed by nausea and vomiting immediately after an initial administration of the alpha-glucosidase inhibitor, voglibose.	subject	subject-race	[ "null" ]
train-249	9804082_2	adverse_event	[ "after" ]	false	We observed 3 diabetic patients with intolerable dizziness followed by nausea and vomiting immediately after an initial administration of the alpha-glucosidase inhibitor, voglibose.	treatment	treatment-drug	[ "voglibose" ]
train-250	9804082_2	adverse_event	[ "after" ]	false	We observed 3 diabetic patients with intolerable dizziness followed by nausea and vomiting immediately after an initial administration of the alpha-glucosidase inhibitor, voglibose.	treatment	treatment-disorder	[ "diabetic" ]
train-251	9804082_2	adverse_event	[ "after" ]	false	We observed 3 diabetic patients with intolerable dizziness followed by nausea and vomiting immediately after an initial administration of the alpha-glucosidase inhibitor, voglibose.	treatment	treatment-route	[ "null" ]
train-252	9804082_2	adverse_event	[ "after" ]	false	We observed 3 diabetic patients with intolerable dizziness followed by nausea and vomiting immediately after an initial administration of the alpha-glucosidase inhibitor, voglibose.	treatment	treatment-dosage	[ "null" ]
train-253	9804082_2	adverse_event	[ "after" ]	false	We observed 3 diabetic patients with intolerable dizziness followed by nausea and vomiting immediately after an initial administration of the alpha-glucosidase inhibitor, voglibose.	treatment	treatment-time_elasped	[ "null" ]
train-254	9804082_2	adverse_event	[ "after" ]	false	We observed 3 diabetic patients with intolerable dizziness followed by nausea and vomiting immediately after an initial administration of the alpha-glucosidase inhibitor, voglibose.	treatment	treatment-duration	[ "null" ]
train-255	9804082_2	adverse_event	[ "after" ]	false	We observed 3 diabetic patients with intolerable dizziness followed by nausea and vomiting immediately after an initial administration of the alpha-glucosidase inhibitor, voglibose.	treatment	treatment-freq	[ "null" ]
train-256	9184269_1	adverse_event	[ "induced" ]	false	Although risk factors for MTX-induced pulmonary toxicity are poorly understood, the presence in 3 out of 5 of our patients of pre-existing lung disease, represented by diffuse interstitial changes on chest X-ray, and mild bronchial asthma in two RA patients and by pulmonary silicosis in the patient with PsA may account...	main-arguments	subject	[ "the presence in 3 out of 5 of our patients of pre-existing lung disease, represented by diffuse interstitial changes on chest X-ray, and mild bronchial asthma in two RA patients and by pulmonary silicosis in the patient with PsA" ]
train-257	9184269_1	adverse_event	[ "induced" ]	false	Although risk factors for MTX-induced pulmonary toxicity are poorly understood, the presence in 3 out of 5 of our patients of pre-existing lung disease, represented by diffuse interstitial changes on chest X-ray, and mild bronchial asthma in two RA patients and by pulmonary silicosis in the patient with PsA may account...	main-arguments	treatment	[ "MTX" ]
train-258	9184269_1	adverse_event	[ "induced" ]	false	Although risk factors for MTX-induced pulmonary toxicity are poorly understood, the presence in 3 out of 5 of our patients of pre-existing lung disease, represented by diffuse interstitial changes on chest X-ray, and mild bronchial asthma in two RA patients and by pulmonary silicosis in the patient with PsA may account...	main-arguments	effect	[ "pulmonary toxicity" ]
train-259	9184269_1	adverse_event	[ "induced" ]	false	Although risk factors for MTX-induced pulmonary toxicity are poorly understood, the presence in 3 out of 5 of our patients of pre-existing lung disease, represented by diffuse interstitial changes on chest X-ray, and mild bronchial asthma in two RA patients and by pulmonary silicosis in the patient with PsA may account...	subject	subject-age	[ "null" ]
train-260	9184269_1	adverse_event	[ "induced" ]	false	Although risk factors for MTX-induced pulmonary toxicity are poorly understood, the presence in 3 out of 5 of our patients of pre-existing lung disease, represented by diffuse interstitial changes on chest X-ray, and mild bronchial asthma in two RA patients and by pulmonary silicosis in the patient with PsA may account...	subject	subject-disorder	[ "pre-existing lung disease, represented by diffuse interstitial changes on chest X-ray, and mild bronchial asthma in two RA patients and by pulmonary silicosis in the patient with PsA" ]
train-261	9184269_1	adverse_event	[ "induced" ]	false	Although risk factors for MTX-induced pulmonary toxicity are poorly understood, the presence in 3 out of 5 of our patients of pre-existing lung disease, represented by diffuse interstitial changes on chest X-ray, and mild bronchial asthma in two RA patients and by pulmonary silicosis in the patient with PsA may account...	subject	subject-gender	[ "null" ]
train-262	9184269_1	adverse_event	[ "induced" ]	false	Although risk factors for MTX-induced pulmonary toxicity are poorly understood, the presence in 3 out of 5 of our patients of pre-existing lung disease, represented by diffuse interstitial changes on chest X-ray, and mild bronchial asthma in two RA patients and by pulmonary silicosis in the patient with PsA may account...	subject	subject-population	[ "3 out of 5" ]
train-263	9184269_1	adverse_event	[ "induced" ]	false	Although risk factors for MTX-induced pulmonary toxicity are poorly understood, the presence in 3 out of 5 of our patients of pre-existing lung disease, represented by diffuse interstitial changes on chest X-ray, and mild bronchial asthma in two RA patients and by pulmonary silicosis in the patient with PsA may account...	subject	subject-race	[ "null" ]
train-264	9184269_1	adverse_event	[ "induced" ]	false	Although risk factors for MTX-induced pulmonary toxicity are poorly understood, the presence in 3 out of 5 of our patients of pre-existing lung disease, represented by diffuse interstitial changes on chest X-ray, and mild bronchial asthma in two RA patients and by pulmonary silicosis in the patient with PsA may account...	treatment	treatment-drug	[ "MTX" ]
train-265	9184269_1	adverse_event	[ "induced" ]	false	Although risk factors for MTX-induced pulmonary toxicity are poorly understood, the presence in 3 out of 5 of our patients of pre-existing lung disease, represented by diffuse interstitial changes on chest X-ray, and mild bronchial asthma in two RA patients and by pulmonary silicosis in the patient with PsA may account...	treatment	treatment-disorder	[ "null" ]
train-266	9184269_1	adverse_event	[ "induced" ]	false	Although risk factors for MTX-induced pulmonary toxicity are poorly understood, the presence in 3 out of 5 of our patients of pre-existing lung disease, represented by diffuse interstitial changes on chest X-ray, and mild bronchial asthma in two RA patients and by pulmonary silicosis in the patient with PsA may account...	treatment	treatment-route	[ "null" ]
train-267	9184269_1	adverse_event	[ "induced" ]	false	Although risk factors for MTX-induced pulmonary toxicity are poorly understood, the presence in 3 out of 5 of our patients of pre-existing lung disease, represented by diffuse interstitial changes on chest X-ray, and mild bronchial asthma in two RA patients and by pulmonary silicosis in the patient with PsA may account...	treatment	treatment-dosage	[ "null" ]
train-268	9184269_1	adverse_event	[ "induced" ]	false	Although risk factors for MTX-induced pulmonary toxicity are poorly understood, the presence in 3 out of 5 of our patients of pre-existing lung disease, represented by diffuse interstitial changes on chest X-ray, and mild bronchial asthma in two RA patients and by pulmonary silicosis in the patient with PsA may account...	treatment	treatment-time_elasped	[ "null" ]
train-269	9184269_1	adverse_event	[ "induced" ]	false	Although risk factors for MTX-induced pulmonary toxicity are poorly understood, the presence in 3 out of 5 of our patients of pre-existing lung disease, represented by diffuse interstitial changes on chest X-ray, and mild bronchial asthma in two RA patients and by pulmonary silicosis in the patient with PsA may account...	treatment	treatment-duration	[ "null" ]
train-270	9184269_1	adverse_event	[ "induced" ]	false	Although risk factors for MTX-induced pulmonary toxicity are poorly understood, the presence in 3 out of 5 of our patients of pre-existing lung disease, represented by diffuse interstitial changes on chest X-ray, and mild bronchial asthma in two RA patients and by pulmonary silicosis in the patient with PsA may account...	treatment	treatment-freq	[ "null" ]
train-271	8936932_1	adverse_event	[ "be" ]	false	Acute esmolol toxicity may be self-limiting because of its extremely short half-life.	main-arguments	subject	[ "null" ]
train-272	8936932_1	adverse_event	[ "be" ]	false	Acute esmolol toxicity may be self-limiting because of its extremely short half-life.	main-arguments	treatment	[ "esmolol" ]
train-273	8936932_1	adverse_event	[ "be" ]	false	Acute esmolol toxicity may be self-limiting because of its extremely short half-life.	main-arguments	effect	[ "toxicity" ]
train-274	8936932_1	adverse_event	[ "be" ]	false	Acute esmolol toxicity may be self-limiting because of its extremely short half-life.	subject	subject-age	[ "null" ]
train-275	8936932_1	adverse_event	[ "be" ]	false	Acute esmolol toxicity may be self-limiting because of its extremely short half-life.	subject	subject-disorder	[ "null" ]
train-276	8936932_1	adverse_event	[ "be" ]	false	Acute esmolol toxicity may be self-limiting because of its extremely short half-life.	subject	subject-gender	[ "null" ]
train-277	8936932_1	adverse_event	[ "be" ]	false	Acute esmolol toxicity may be self-limiting because of its extremely short half-life.	subject	subject-population	[ "null" ]
train-278	8936932_1	adverse_event	[ "be" ]	false	Acute esmolol toxicity may be self-limiting because of its extremely short half-life.	subject	subject-race	[ "null" ]
train-279	8936932_1	adverse_event	[ "be" ]	false	Acute esmolol toxicity may be self-limiting because of its extremely short half-life.	treatment	treatment-drug	[ "esmolol" ]
train-280	8936932_1	adverse_event	[ "be" ]	false	Acute esmolol toxicity may be self-limiting because of its extremely short half-life.	treatment	treatment-disorder	[ "null" ]
train-281	8936932_1	adverse_event	[ "be" ]	false	Acute esmolol toxicity may be self-limiting because of its extremely short half-life.	treatment	treatment-route	[ "null" ]
train-282	8936932_1	adverse_event	[ "be" ]	false	Acute esmolol toxicity may be self-limiting because of its extremely short half-life.	treatment	treatment-dosage	[ "null" ]
train-283	8936932_1	adverse_event	[ "be" ]	false	Acute esmolol toxicity may be self-limiting because of its extremely short half-life.	treatment	treatment-time_elasped	[ "null" ]
train-284	8936932_1	adverse_event	[ "be" ]	false	Acute esmolol toxicity may be self-limiting because of its extremely short half-life.	treatment	treatment-duration	[ "null" ]
train-285	8936932_1	adverse_event	[ "be" ]	false	Acute esmolol toxicity may be self-limiting because of its extremely short half-life.	treatment	treatment-freq	[ "null" ]
train-286	7835785_2	adverse_event	[ "with" ]	false	The association with prolonged unopposed estrogen-like stimulation with tamoxifen as a possible factor in the development of ovarian endometrioid carcinoma is discussed.	main-arguments	subject	[ "null" ]
train-287	7835785_2	adverse_event	[ "with" ]	false	The association with prolonged unopposed estrogen-like stimulation with tamoxifen as a possible factor in the development of ovarian endometrioid carcinoma is discussed.	main-arguments	treatment	[ "prolonged unopposed estrogen-like stimulation with tamoxifen" ]
train-288	7835785_2	adverse_event	[ "with" ]	false	The association with prolonged unopposed estrogen-like stimulation with tamoxifen as a possible factor in the development of ovarian endometrioid carcinoma is discussed.	main-arguments	effect	[ "development of ovarian endometrioid carcinoma" ]
train-289	7835785_2	adverse_event	[ "with" ]	false	The association with prolonged unopposed estrogen-like stimulation with tamoxifen as a possible factor in the development of ovarian endometrioid carcinoma is discussed.	subject	subject-age	[ "null" ]
train-290	7835785_2	adverse_event	[ "with" ]	false	The association with prolonged unopposed estrogen-like stimulation with tamoxifen as a possible factor in the development of ovarian endometrioid carcinoma is discussed.	subject	subject-disorder	[ "null" ]
train-291	7835785_2	adverse_event	[ "with" ]	false	The association with prolonged unopposed estrogen-like stimulation with tamoxifen as a possible factor in the development of ovarian endometrioid carcinoma is discussed.	subject	subject-gender	[ "null" ]
train-292	7835785_2	adverse_event	[ "with" ]	false	The association with prolonged unopposed estrogen-like stimulation with tamoxifen as a possible factor in the development of ovarian endometrioid carcinoma is discussed.	subject	subject-population	[ "null" ]
train-293	7835785_2	adverse_event	[ "with" ]	false	The association with prolonged unopposed estrogen-like stimulation with tamoxifen as a possible factor in the development of ovarian endometrioid carcinoma is discussed.	subject	subject-race	[ "null" ]
train-294	7835785_2	adverse_event	[ "with" ]	false	The association with prolonged unopposed estrogen-like stimulation with tamoxifen as a possible factor in the development of ovarian endometrioid carcinoma is discussed.	treatment	treatment-drug	[ "tamoxifen" ]
train-295	7835785_2	adverse_event	[ "with" ]	false	The association with prolonged unopposed estrogen-like stimulation with tamoxifen as a possible factor in the development of ovarian endometrioid carcinoma is discussed.	treatment	treatment-disorder	[ "null" ]
train-296	7835785_2	adverse_event	[ "with" ]	false	The association with prolonged unopposed estrogen-like stimulation with tamoxifen as a possible factor in the development of ovarian endometrioid carcinoma is discussed.	treatment	treatment-route	[ "null" ]
train-297	7835785_2	adverse_event	[ "with" ]	false	The association with prolonged unopposed estrogen-like stimulation with tamoxifen as a possible factor in the development of ovarian endometrioid carcinoma is discussed.	treatment	treatment-dosage	[ "null" ]
train-298	7835785_2	adverse_event	[ "with" ]	false	The association with prolonged unopposed estrogen-like stimulation with tamoxifen as a possible factor in the development of ovarian endometrioid carcinoma is discussed.	treatment	treatment-time_elasped	[ "null" ]
train-299	7835785_2	adverse_event	[ "with" ]	false	The association with prolonged unopposed estrogen-like stimulation with tamoxifen as a possible factor in the development of ovarian endometrioid carcinoma is discussed.	treatment	treatment-duration	[ "null" ]
train-300	7835785_2	adverse_event	[ "with" ]	false	The association with prolonged unopposed estrogen-like stimulation with tamoxifen as a possible factor in the development of ovarian endometrioid carcinoma is discussed.	treatment	treatment-freq	[ "null" ]

Subsets and Splits

No community queries yet

The top public SQL queries from the community will appear here once available.